US weight loss centre starts using Tethys' diabetes risk score
This article was originally published in Clinica
Structure House, a weight loss centre in Durham, North Carolina, has initiated a study using Tethys Bioscience's PreDx Diabetes Risk Score (DRS) on 50 participants in its 28-day programme. PreDx DRS is a blood test that measures a person's risk of developing diabetes within five years. Emeryville, California-based Tethys hopes that it will help doctors target preventative strategies, such as weight loss programmes, to the most at-risk individuals. The study will use PreDx DRS to assess whether Structure House's intensive lifestyle change programme can alter patients' probability of developing diabetes. It will also evaluate whether more specific feedback on diabetes risk at the start of the regimen will increase the subjects' motivation to change their lifestyle.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.